Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Combined With HAG for R/R T-ALL/LBL
NCT06742463Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in t-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete Remission with or without Incomplete Peripheral Blood Cell Recovery Rate. Started Dec 2024; status: recruiting.
02
Drugs
venetoclax
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT06742463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06742463.